论文部分内容阅读
[目的] 观察拉米夫定联合三甲益肝冲剂对慢性乙型肝炎(CHB)血清肝纤维化指标的影响。[方法] 将106例CHB随机分为对照(30例)、拉米夫定(32 例)、拉米夫定联合三甲益肝冲剂(44 例)治疗组,疗程 12 个月。采用放射免疫法检测各组治疗前后血清透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(Ⅳ C)水平。[结果] 拉米夫定及联合治疗组治疗后各项血清肝纤维化指标均明显下降,联合治疗组优于拉米夫定组。[结论] 拉米夫定联合三甲益肝冲剂能显著降低CHB患者血清肝纤维化指标。
[Objective] To observe the effect of lamivudine combined with Sankinayigan granule on serum hepatic fibrosis index of chronic hepatitis B (CHB). [Method] 106 CHB patients were randomly divided into control group (n = 30), lamivudine group (n = 32) and lamivudine combined with SJKYI group (n = 44). The course of treatment was 12 months. The levels of serum hyaluronic acid (HA), laminin (LN), type Ⅲ procollagen (Ⅲ) and type Ⅳ collagen (Ⅳ C) were measured by radioimmunoassay before and after treatment. [Results] The serum levels of hepatic fibrosis were significantly decreased in the lamivudine and combination therapy groups, and the combination therapy group was superior to the lamivudine group. [Conclusion] Lamivudine combined with SJTYI can significantly reduce the serum levels of liver fibrosis in CHB patients.